FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Fiche publication
Date publication
janvier 2015
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain
Tous les auteurs :
Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R, Terrebonne E, De La Fouchardière C, Manfredi S, Solub D, Lécaille C, Thirot Bidault A, Carbonnel F, Taieb J
Lien Pubmed
Résumé
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (LAPA).
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, administration & dosage, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Female, Fluorouracil, administration & dosage, Follow-Up Studies, Humans, Irinotecan, Leucovorin, administration & dosage, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, drug therapy, Neoplasm Staging, Pancreatic Neoplasms, drug therapy, Prognosis, Prospective Studies, Survival Rate
Référence
Ann. Surg. Oncol.. 2015 Jan;22(1):295-301